Panacea Biotec Q3 net loss at Rs 62 cr

Net sales of the company rose to Rs 166.28 cr for the quarter under consideration from Rs 152.98 cr

Image
Press Trust of India New Delhi
Last Updated : Feb 08 2013 | 6:14 PM IST
Pharma firm Panacea Biotec today reported net loss of 62.28 crore for the third quarter ended December 31, 2012.

The company had posted a net loss of Rs 71.72 crore for the corresponding period previous fiscal.

Net sales of the company rose to Rs 166.28 crore for the quarter under consideration from Rs 152.98 crore for the same period year ago, Panacea Biotec said in a filing to the BSE.

Also Read

"The company has got orders from the  Government of India for supply of Trivalent Oral Polio Vaccines and Bivalent Oral Polio Vaccines worth Rs 187.61 crore to be supplied during the period December 2012 till May 2013 to meet the requirements of National Immunisation Days and Supplementary National Immunisation Days," Panacea Biotec said.

Shares of Panacea Biotec today closed at Rs 129.25 apiece on the BSE, down 2.49% from their previous close.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 08 2013 | 6:11 PM IST

Next Story